Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00652626 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00652626 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 31 participants.
The verdict
NCT00652626, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate three things. The first being whether azacitidine is absorbed in the body at the same rate or proportion for different concentrations. The second is to determine the effect renal impairment has or does not have on the absorption of azacitidine. The third is to determine if azacitidine is safe and well tolerated in patients with renal function impairment.
Interventions
- DRUG azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-11-01 |
| Est. Completion | 2012-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00652626
The ClinicalTrials.gov registry entry for NCT00652626 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which azacitidine is the first listed.
NCT00652626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00652626 about?
NCT00652626 is a clinical study titled "Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function". The purpose of this study is to evaluate three things. The first being whether azacitidine is absorbed in the body at the same rate or proportion for different concentrations. The second is to determine the effect renal impairment has or does not have on the absorption of azacitidine. The third is t...
What is the current status of trial NCT00652626?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2008-11-01. Estimated completion is 2012-07-01.
What interventions are being tested in trial NCT00652626?
The interventions under investigation include: azacitidine (DRUG).
Who is sponsoring clinical trial NCT00652626?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.